Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$13.52

0.07 (0.52%)

12:31
11/23/16
11/23
12:31
11/23/16
12:31

Axovant Sciences outlook unchanged on Lilly's solanezumab failure, says Baird

  • 29

    Nov

AXON Axovant Sciences
$13.52

0.07 (0.52%)

09/22/16
JMPS
09/22/16
NO CHANGE
JMPS
Axovant Sciences weakness an opportunity, says JMP Securities
09/22/16
CHDN
09/22/16
NO CHANGE
Target $8
CHDN
Sell
Recent failures of 5-HT6 competitors reinforce Axovant risks, says Chardan
After Lundbeck reported that its 5-HT6 antagonist, idalopirdine, did not meet the primary endpoint in the first of three phase III studies in mild-to-moderate Alzheimer's disease patients, Chardan analyst Gbola Amusa noted that this is the second recent failure of a mid-to-late-stage 5-HT6 antagonist coming on the heels of Pfizer's (PFE) prior miss. Amusa anticipates that some in the market will see limited read-across from Lundbeck to Axovant (AXON), but he thinks Pfizer's and Lundbeck's setbacks reinforce the risks for the 5-HT6 antagonist class in Alzheimer's. The analyst reiterates his Sell rating and $8 price target on Axovant shares.
09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.

TODAY'S FREE FLY STORIES

HLX

Helix Energy

$7.41

-0.32 (-4.14%)

19:24
02/20/17
02/20
19:24
02/20/17
19:24
Earnings
Helix Energy reports Q4 EPS with items (46c), may not compare to consensus (6c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CSII

Cardiovascular Systems

$29.19

0.76 (2.67%)

19:21
02/20/17
02/20
19:21
02/20/17
19:21
Hot Stocks
Cardiovascular Systems reports one-year data from COAST study »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMT

America's Car-Mart

$38.85

-1.15 (-2.88%)

19:17
02/20/17
02/20
19:17
02/20/17
19:17
Earnings
America's Car-Mart reports Q3 EPS 35c, may not compare to consensus 64c »

Reports Q3 revenue $139M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:12
02/20/17
02/20
19:12
02/20/17
19:12
Earnings
Rogers Corporation sees Q1 adjusted EPS $1.09-$1.19, consensus 99c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:11
02/20/17
02/20
19:11
02/20/17
19:11
Earnings
Rogers Corporation reports Q4 EPS 94c, consensus 82c »

Reports Q4 revenue $173M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

, FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

19:04
02/20/17
02/20
19:04
02/20/17
19:04
Hot Stocks
Hancock Holding says gets approval to close First NBC Bank transaction »

Hancock Holding (HBHC)…

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$119.95

0.77 (0.65%)

19:03
02/20/17
02/20
19:03
02/20/17
19:03
Earnings
Nordson sees Q2 EPS $1.21-$1.33, consensus $1.22 »

Sees Q2 revenue up 3%-7%.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:01
02/20/17
02/20
19:01
02/20/17
19:01
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson says order rates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:00
02/20/17
02/20
19:00
02/20/17
19:00
Earnings
Nordson reports Q1 EPS 86c, consensus 82c »

Reports Q1 revenue $407M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

18:57
02/20/17
02/20
18:57
02/20/17
18:57
Hot Stocks
Nordson to acquire Vention AT for $705M »

Nordson announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:55
02/20/17
02/20
18:55
02/20/17
18:55
Earnings
Community Health sees FY17 cont ops EPS 30c-$1.10 »

EPS consensus 61c. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:51
02/20/17
02/20
18:51
02/20/17
18:51
Earnings
Community Health reports Q4 adjusted EPS 46c, may not compare to consensus 13c »

Reports Q4 net operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

HSIC

Henry Schein

$168.11

0.86 (0.51%)

18:47
02/20/17
02/20
18:47
02/20/17
18:47
Hot Stocks
Henry Schein to acquire Southern Anesthesia + Surgical »

Henry Schein announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 24

    Feb

UIHC

United Insurance

$15.95

0.01 (0.06%)

18:45
02/20/17
02/20
18:45
02/20/17
18:45
Earnings
United Insurance reports Q4 EPS (49c), consensus (39c) »

Reports Q4 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:40
02/20/17
02/20
18:40
02/20/17
18:40
Earnings
Breaking Earnings news story on Vipshop »

Vipshop sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:39
02/20/17
02/20
18:39
02/20/17
18:39
Earnings
Vipshop reports Q4 adjusted income per ADS 23c, consensus 21c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

, BK

BNY Mellon

$47.14

0.07 (0.15%)

18:36
02/20/17
02/20
18:36
02/20/17
18:36
Hot Stocks
Wells Fargo names two new independent directors »

The board of Wells Fargo…

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

BK

BNY Mellon

$47.14

0.07 (0.15%)

SPLS

Staples

$9.31

0.04 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

BIOA

BioAmber

$3.66

-0.07 (-1.88%)

18:33
02/20/17
02/20
18:33
02/20/17
18:33
Hot Stocks
BioAmber says CEO Huc resigns, COO Orecchioni appointed president »

BioAmber announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBB

Cincinnati Bell

$19.85

-0.65 (-3.17%)

18:31
02/20/17
02/20
18:31
02/20/17
18:31
Hot Stocks
Cincinnati Bell subsidiary acquires SunTel Services »

CBTS, a wholly-owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VZ

Verizon

$49.19

0.73 (1.51%)

, AAPL

Apple

$135.72

0.375 (0.28%)

18:23
02/20/17
02/20
18:23
02/20/17
18:23
Hot Stocks
Verizon appoints Apple's Andrew McKechnie as creative chief of in-house agency »

Verizon (VZ) announced…

VZ

Verizon

$49.19

0.73 (1.51%)

AAPL

Apple

$135.72

0.375 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 13

    Mar

NEE

NextEra Energy

$126.86

0.67 (0.53%)

18:19
02/20/17
02/20
18:19
02/20/17
18:19
Hot Stocks
NextEra Energy subsidiary says expands solar energy projects »

NextEra Energy subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SNX

SYNNEX

$118.37

-0.23 (-0.19%)

18:14
02/20/17
02/20
18:14
02/20/17
18:14
Hot Stocks
Raritan announces distribution agreement with SYNNEX »

Raritan, a provider of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$14.91

-0.16 (-1.06%)

18:06
02/20/17
02/20
18:06
02/20/17
18:06
Hot Stocks
Freeport McMoRan says fails to reach deal with Indonesia, sees Q1 sales impact »

Freeport McMoRan issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WEN

Wendy's

$14.13

0.44 (3.21%)

18:01
02/20/17
02/20
18:01
02/20/17
18:01
Hot Stocks
Delight Restaurant Group acquires 30 Wendy's restaurants »

Delight Restaurant Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CMG

Chipotle

$427.61

2.85 (0.67%)

17:59
02/20/17
02/20
17:59
02/20/17
17:59
Hot Stocks
Chipotle says 'Smarter Pickup Times' technology rolled out across U.S. »

Chipotle announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.